MoonLake Immunotherapeutics (MLTX) Cash & Equivalents (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $298.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 9.91% year-over-year to $298.5 million; the TTM figure through Mar 2026 stood at $298.5 million (up 9.91% YoY), while the FY2025 annual figure was $334.5 million, up 85.4% from the prior year.
• Cash & Equivalents was $298.5 million for Q1 2026 at MoonLake Immunotherapeutics, down from $334.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $501.8 million in Q2 2023 to a low of $23336.0 in Q1 2022.
• Historically, Cash & Equivalents has averaged $270.1 million across 5 years, with a median of $312.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 98.01% in 2022, then jumped 214714.87% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $39.5 million in 2022, then surged by 1042.04% to $451.2 million in 2023, then plunged by 60.01% to $180.4 million in 2024, then soared by 85.4% to $334.5 million in 2025, then slipped by 10.77% to $298.5 million in 2026.
• The last three Cash & Equivalents figures came in at $298.5 million (Q1 2026), $334.5 million (Q4 2025), and $350.7 million (Q3 2025), per Business Quant data.